2024
Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study
Petrakis I, Nolen T, Vandergrift N, Hirsch S, Krystal J, De Vivo M, Sabados J, Pisani E, Newcomb J, Kosten T. Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study. American Journal On Addictions 2024 PMID: 39152094, DOI: 10.1111/ajad.13637.Peer-Reviewed Original ResearchPathophysiology of posttraumatic stress disorderAlcohol use disorderSubjective effects of alcoholEffects of alcoholUse disorderComorbid alcohol use disorderAlcohol cue reactivityPosttraumatic stress disorderCrossover laboratory studyCue reactivityAlcohol cravingNoradrenergic dysregulationStress disorderBlood pressureSubjective effectsEthanol administrationClinically significant adverse effectsPharmacotherapeutic approachesTest daysReceptor agonistsPotential treatmentDouble-blind fashionCravingDrinking alcoholDisorders
2023
Progesterone Attenuates the Stress Response in Individuals with Alcohol Dependence and Post-Traumatic Stress Disorder – A Pilot Study
Ralevski E, Newcomb J, Pisani E, DeNegre D, Peltier M, Jane J, Yoon G, Petrakis I. Progesterone Attenuates the Stress Response in Individuals with Alcohol Dependence and Post-Traumatic Stress Disorder – A Pilot Study. Journal Of Dual Diagnosis 2023, 20: 39-51. PMID: 38147491, PMCID: PMC11214330, DOI: 10.1080/15504263.2023.2294989.Peer-Reviewed Original ResearchAlcohol use disorderStress-induced cravingCognitive performanceNegative affectNeutral scriptsStress disorderPost-traumatic stress disorderComorbid alcohol use disorderTraumatic Stress DisorderMeasures of cravingCurrent alcohol use disorderPositive emotionsTrauma scriptsPhysiological measuresCravingStress-induced symptomsTest sessionsPTSDAnxietyAffectUse disordersLaboratory sessionsCocaine dependenceAlcohol dependenceIndividualsComorbid alcohol use disorder and posttraumatic stress disorder: A proof‐of‐concept randomized placebo‐controlled trial of buprenorphine and naltrexone combination treatment
Davis L, Petrakis I, Pilkinton P, Nolen T, Vandergrift N, Hirsch S, Norrholm S, Kosten T. Comorbid alcohol use disorder and posttraumatic stress disorder: A proof‐of‐concept randomized placebo‐controlled trial of buprenorphine and naltrexone combination treatment. Alcohol Clinical And Experimental Research 2023, 47: 1756-1772. PMID: 37468230, DOI: 10.1111/acer.15155.Peer-Reviewed Original ResearchComorbid alcohol use disorderAlcohol use disorderPosttraumatic stress disorderPlacebo-controlled trialWorld Health OrganizationReceptor antagonismOpioid receptorsUse disordersExtended-release injectable naltrexoneKappa-opioid receptor antagonistStress disorderClinician-Administered PTSD ScalePrimary composite outcomeEffective pharmacologic treatmentOpioid receptor antagonistOpioid receptor antagonismMu-opioid receptorsCombination of buprenorphineBinary primary outcomeTimeline Follow-BackAUD outcomesBuprenorphine 2Injectable placeboPrimary timepointInjectable naltrexone
2018
Pharmacological and Psychological Treatments for Comorbid Alcohol Use Disorder and Depressive Disorder: a Review
Yoon G, Petrakis I. Pharmacological and Psychological Treatments for Comorbid Alcohol Use Disorder and Depressive Disorder: a Review. Current Addiction Reports 2018, 5: 312-322. DOI: 10.1007/s40429-018-0213-z.Peer-Reviewed Original ResearchComorbid alcohol use disorderAlcohol use disorderPsychological interventionsCognitive-behavioral treatmentUse disordersPsychological treatmentDepressive disorderMotivational interviewingComorbid disordersMixed resultsDisordersInterventionRecent FindingsWePharmacological interventionsCurrent reviewEffective treatmentFurther researchReviewThe goalInterviewingAntidepressantsPatientsTreatmentDepressionTrialsEfficacy